TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03682120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H7N9
Description: Monovalent inactivated, subunit influenza virus vaccine containing the HA and NA from influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS genes from A/Puerto Rico/8/1934 (H1N1).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H7N9
Description: Monovalent inactivated, subunit influenza virus vaccine containing the HA and NA from influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS genes from A/Puerto Rico/8/1934 (H1N1).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H7N9
Description: Monovalent inactivated, subunit influenza virus vaccine containing the HA and NA from influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS genes from A/Puerto Rico/8/1934 (H1N1).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H7N9
Description: Monovalent inactivated, subunit influenza virus vaccine containing the HA and NA from influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS genes from A/Puerto Rico/8/1934 (H1N1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Diluent for Influenza Virus Vaccine.
Study: NCT02184572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix
Description: 1 dose administered subcutaneously in the triceps region of left arm at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R II
Description: 1 dose administered subcutaneously in the triceps region of left arm at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax
Description: 1 dose administered subcutaneously in the triceps region of right arm at Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax
Description: 1 dose administered subcutaneously in the triceps region of right arm at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix
Description: 1 dose administered intramuscularly in the anterolateral region of the right thigh at Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: 1 dose administered intramuscularly in the anterolateral region of the right thigh at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: 1 dose administered intramuscularly in the anterolateral region of the left thigh at Day 0 to subjects recruited in US

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13
Description: 1 dose administered intramuscularly in the anterolateral region of the left thigh at Day 0 to subjects recruited in US
Study: NCT02495038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% reduction of combination of Esmeron® and Nimbex®
Description: Patients were randomly assigned to each group by opening of sealed allocation envelope. After collection of data, allocation number was matched with each group. The participants matched at Group S were administered with NMBAs reduced 10% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each drug dosage was determined by allocation number. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% reduction of combination of Esmeron® and Nimbex®
Description: The participants matched at Group L were administered with NMBAs reduced 20% of each ED95.
Study: NCT03684369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: Commercially available device will be used to apply weak electrical currents to arm and leg muscles in each of 18 treatment sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: Commercially available device will be used to apply weak electrical currents to arm and leg muscles in each of 18 treatment sessions.
Study: NCT02350764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pilimumab
Study: NCT03785223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride Controlled-Release Capsules
Description: 25 mg methylphenidate hydrochloride- titrated as tolerated up to a maximum 4 capsules daily (25 mg- 100 mg total dose)~At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. 50 mg of methylphenidate hydrochloride per day (i.e. 2 capsules/day) is the minimum dose that must be achieved. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11, no further dose changes will occur.
Study: NCT03682120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Diluent for Influenza Virus Vaccine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Diluent for Influenza Virus Vaccine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Diluent for Influenza Virus Vaccine.
Study: NCT03618056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX® B/E
Description: Administered by intramuscular injection
Study: NCT00591695

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent bridge to surgery + elective surgery
Description: positioning in emergency of a metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency Surgery
Description: Emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
Study: NCT03897543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX196
Description: ABX196 will be administered as an IM injection 120 minutes (+/- 15 minutes) after the completion of the nivolumab infusion on Day 1 of every other 28-Day treatment cycle (i.e., every 8 weeks).
Study: NCT01970163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DermACELL
Description: Acellular dermal matrix is applied at Baseline visit. The study product may be reapplied an additional time (between Weeks 2 and 12 for venous stasis ulcers and between Weeks 3 and 12 for diabetic foot ulcers).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GraftJacket
Description: Acellular dermal matrix applied at Baseline visit. May be reapplied one additional time during study (between Week 2 and 12 for venous stasis ulcers and Week 3 and 12 for diabetic foot ulcers).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Care Dressings
Description: Depending on the state of the wound (dry or moist), different types of nonadherent dressings would be utilized as the primary dressing:~* If the wound is dry, a nonadherent dressing, such an oil emulsion dressing, may be appropriate, as these dressings tend to donate moisture to the wound.~* Hydrogels can also be used if the wound is in need of moisture.~* For a wound that is more moist, a more absorptive dressing may be more appropriate to help reduce potential for maceration.~A secondary dressing may be desired to add either loft or cushion.
Study: NCT04935983

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High CHO
Description: Diet with high carbohydrate content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low CHO
Description: Diet with low carbohydrate content
Study: NCT02758535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coaxial renal biopsy
Description: In this method, a larger introducing needle is used for the puncture. The introducing needle is advanced just to the outer cortex of the kidney, and the needle angle is adjusted so that the needle pathway became mostly in the renal cortex, then the biopsy needle is inserted throughout the introducing needle and at least 4 cores are obtained. In this technique, the skin surface is punctured only once during the procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noncoaxial renal biopsy
Description: In this method, introducing needle is not used. Biopsy needle punctures the skin surface and the needle is advanced to about 10-15 mm into the renal cortex, and tissue sampling is done. After each sampling, the needle is removed and then for the next biopsy, the whole procedure is repeated until four cores being taken.
Study: NCT01515228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xience Prime
Description: everolimus-eluting stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cilotax stent
Description: paclitaxel with cilostazol dual drug eluting stent implantation
Study: NCT03785223

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11 no further dose changes will occur.
Study: NCT02619916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Description: The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 60 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 60 minutes.
Study: NCT01765959

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupuncture (AA)
Description: Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
Study: NCT03633084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBM-007 Injectable Solution
Description: (No additional description)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBM-007 Injectable Solution
Description: (No additional description)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBM-007 Injectable Solution
Description: (No additional description)
Study: NCT01119547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise in a group
Description: The patient do their individual exercise program in a group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: The patient exercise their individual program at home during 6 v.
Study: NCT01557829

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior lumbar interbody fusion with a PEEK cage
Description: PEEK cage suitable for oblique placement in the lumbar spine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion with a Valeo OL cage
Description: Posterior lumbar interbody fusion with a single Valeo OL ceramic cage.
Study: NCT01083667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Open Label, dose escalating,
Study: NCT02581254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thin Wire Snare

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thick Wire Snare
Study: NCT00604968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caelyx (pegylated liposomal doxorubicin; SCH 200746)
Description: Caelyx will be administered intravenously at a dose of 40 mg/m\^2 on day one every 4 weeks until progression, or unacceptable toxicity, or other reason to discontinue the study treatment. The drug is diluted in 250 ml glucose 5% (500 ml for doses \>=90 mg).
Study: NCT01709188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical Dual Task Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking and Talking
Study: NCT01439945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium oxide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium oxide
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study: NCT04082663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Mouthpiece
Description: Participants will complete motor tasks with and without the dental mouthpiece during the in-person baseline visit. They will also be asked to wear the mouthpiece for one month, and complete sleep and quality of life questionnaires before and after wearing the mouthpiece.
Study: NCT01893333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve sparing radical hysterectomy
Description: Nerve sparing radical hysterectomy~1. sparing hypogastric nerve~2. sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament~3. sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve sparing radical hysterectomy
Description: Nerve sparing radical hysterectomy~1. sparing hypogastric nerve~2. sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament~3. sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve
Study: NCT01172015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Study: NCT05438381

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic Restorative Technique (ART)
Description: Glass ionomer capsule (GC, USA)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SMART Technique
Description: silver diamine fluoride (SDF) then glass ionomer cement capsule (GC, USA)
Study: NCT04749381

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: acupoint with TCM
Description: The acupoint application was made of traditional Chinese medicine (TCM), and the therapeutic effect was produced through the stimulation of TCM drugs and acupoints.
Study: NCT02123290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265 xmg
Description: Dose of DSM265 to be determined based on the results of the first cohort
Study: NCT04749381

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: acupoint with placebo
Description: The placebo acupoint application was made of black beans and honey, which shares the similar shape and smell of the experiment group, applied at the same acupoints.
Study: NCT03828487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo O3 Neonatal Sensors
Description: Regional Oximetry sensor for Neonates

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 510(k) cleared sensor
Description: Cleared Regional Oximetry sensor for Neonates
Study: NCT01232478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Adherence Program (CAP)
Description: The Comprehensive Adherence Program (CAP) consists of training in the CF My Way program (a validated problem-solving adherence promotion intervention).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Adherence Program (CAP)
Description: The Comprehensive Adherence Program (CAP) consists of training in the CF My Way program (a validated problem-solving adherence promotion intervention).
Study: NCT02549716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: Patients in this group will receive IV acetaminophen and an oral placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen
Description: Patients in this group will receive oral acetaminophen and an IV saline solution placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral placebo
Description: Patients who receive IV acetaminophen will also receive an oral placebo with their IV treatments (every 6 hours for a 14 day period).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV placebo
Description: Patients who receive oral acetaminophen will also receive a saline solution placebo at the same time that they receive the oral acetaminophen treatment (every 6 hours for 14 days).
Study: NCT04418856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Glasses (Experimental)
Description: The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similar to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Glasses (Experimental)
Description: The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similar to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light Glasses (Comparison)
Description: The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similar to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light Glasses (Comparison)
Description: The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similar to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
Study: NCT03158766

Intervention type: OTHER
Intervention: Microdiscectomy
Description: It will be an observational study without interventions. Subjects with diagnose of lumbar disc herniation undergoing open decompression surgery (microdiscectomy) will be included and analyzed. There will be no direct intervention to the patient proposed by the study.
Study: NCT01813890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 mg
Description: Tapentadol IR 50 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 75 mg
Description: Tapentadol IR 75 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
Study: NCT01602055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Single dose 500 mg of film coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Single dose 500 mg of film coated tablet
Study: NCT05708807

Intervention type: OTHER
Intervention: Observational - all
Description: All stroke patients are included.
Study: NCT04186455

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: proseal
Description: laryngeal mask proseal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: proseal
Description: laryngeal mask proseal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: baska-mask
Description: laryngeal mask baska-mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: baska-mask
Description: laryngeal mask baska-mask
Study: NCT03892161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 800/100 mg tablet
Description: Standard dose DRV/r administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 800/100 mg tablet
Description: Standard dose DRV/r administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 800/100 mg tablet
Description: Standard dose DRV/r administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 800/100 mg tablet
Description: Standard dose DRV/r administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 800/100 mg tablet
Description: Standard dose DRV/r administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin 600mg QD tablet and DTG 50mg BD
Description: Rifampicin and DTG added

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin 600mg QD tablet and DTG 50mg BD
Description: Rifampicin and DTG added

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin 600mg QD tablet and DTG 50mg BD
Description: Rifampicin and DTG added

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin 600mg QD tablet and DTG 50mg BD
Description: Rifampicin and DTG added